时间标签：数据日期 2026-10-31 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/28–2026/10/31 ｜ 情报发生日期 2026-10-31
研究问题
They reflect a gap that exists across clinical settings, between what genomic science already knows and what actually happens when a patient walks into a clinic.；This review is written to address that gap directly, with a particular focus on the Indian population and the underexplored regulatory gene GLIS3.；However, interpatient genetic heterogeneity limits the universal applicability of such standardized protocols.
方法
Search terms included combinations of the following: “pharmacogenomics,” “diabetes mellitus,” “MODY,” “GLIS3,” “precision medicine,” “maturity-onset diabetes of the young,” “SLC22A1,” “PPARG,” “metformin pharmacogenetics,” “beta-cell dysfunction,” “Indian population genomics,” and “polygenic risk scores.” Additional searches were conducted specifically for GLIS3-related studies using terms including “GLIS3 neonatal diabetes,” “GLIS3 Type 1 diabetes,” “GLIS3 Type 2 diabetes,” “GLIS3 beta-cell,” and “GLIS3 South Asian populations.” Studies were included if they (i) reported original pharmacogenomic data in diabetes; (ii) reviewed gene-drug interactions relevant to antidiabetic therapy; (iii) described clinical outcomes in monogenic or polygenic diabetes in relation to genetic variants; or (iv) provided population-specific genomic data with relevance to Indian or South Asian cohorts.
核心结论
A significant number of people develop diabetes despite having a healthy weight, a good diet, and an active lifestyle.；Because in many cases, the real driver is not what they ate or how much they exercised.；This represents a clinically significant observation that modern diabetes care has been slow to fully incorporate. ‖ 结论：The implementation of these strategies warrants serious policy and clinical consideration.
局限
The implementation of these strategies warrants serious policy and clinical consideration.
对本项目的价值
★☆☆☆☆ 代谢轴既干预敏感性最高，也是老药新用供给最充足的来源。
全文来源
PMC JATS 全文（正文 48,282 字符，已过标题/DOI 逐字归属校验）
原文题录
- 英文标题：Towards precision medicine in diabetes: pharmacogenomic approaches for MODY and type 2 diabetes with insights from GLIS3 gene variants.
- 期刊与标识：Front Endocrinol (Lausanne) · PMID 42959644 · DOI 10.3389/fendo.2026.1871527
C 级证据分级：C 级（预印本 / 观点评论，非原始研究）
本文属观点/评论类文献，不是原始研究。其论点依赖于作者对既有证据的梳理与判断，不构成新的实验证据。本站标注 C 级即为此意——阅读时请把它当作「领域内的思考框架」，而非「研究发现」。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」撰写，依据已获取的期刊全文（方法、样本量与结论已回到原文核对）；未能获取全文的同批条目另行标注「摘要级」，全程未做任何数值推算补全。